Page 29 - Pfizer
Pfizer to stop manufacturing operations in Chennai, Aurangabad units
Over 1,700 employees were working in these two facilities
 "Pfizer to stop manufacturing operations in Chennai, Aurangabad units")
Pfizer Q2 profit dips 13.81% to Rs 958 million, revenue drops marginally
Revenue from operations of the company stood at Rs 5.19 billion in the quarter
 "Pfizer Q2 profit dips 13.81% to Rs 958 million, revenue drops marginally")
Pfizer cuts revenue forecast on supply shortage at sterile-injections biz
Pfizer has been tackling supply shortage issues at its sterile injectable products unit for at least a year
Pfizer replaces long-time CEO Ian Read with veteran Albert Bourla
Pfizer is contending with the expiry of patents on some of its blockbuster drugs
Pfizer stops production at Tamil Nadu plant after 11 USFDA observations
Firm says it is disappointed with the outcome of the inspection
 "Pfizer stops production at Tamil Nadu plant after 11 USFDA observations")
US drugmaker Pfizer says it will split business into three units
The three new units are innovative medicines, established medicines and consumer healthcare
 "US drugmaker Pfizer says it will split business into three units")
Pfizer rolls back drug price hikes temporarily after talking with Trump
The Trump administration has not yet taken significant action to lower drug prices
Pfizer hits an over two-year high ahead of March quarter results
The stock was up 5% to Rs 2,434 on the BSE in intra-day trade, trading at its highest level since January 4, 2016.
No dearth of suitors for consumer health business, says Pfizer
Pfizer said the supply challenges would have a negative impact of "several hundred million dollars" this year, moderating in 2018
 "No dearth of suitors for consumer health business, says Pfizer")
Pfizer may sell or spin off its $15-billion consumer healthcare business
Germany's Merck KGaA is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion
 "Pfizer may sell or spin off its $15-billion consumer healthcare business")
Patent to Pfizer could delay Indian vaccines for pneumonia
With global pharmaceutical giant Pfizer getting a patent last month for its pneumonia vaccine, Indian companies' plans to introduce cheaper products could get delayed.Pneumonia kills 200,000 children in India every year. The vaccine is available in the private market from two global pharma giants, Pfizer and GlaxoSmithKline (GSK).Pfizer's vaccine, called PCV13 and marketed as Prevnar13, provides protection against 13 strains of the the streptococcus pneumoniae bacteria. GSK's product can provide protection against 10 strains. Four Indian companies - Serum Institute, Panacea Biotec, Biological E and Tergene Biotech - have pneumococcal conjugate vaccine (PCV) products in the pipeline, according to Sathguru Management Consultant, which had earlier this year made a report on the Indian vaccine market for the Confederation of Indian Industry (CII)."Pfizer's patent doesn't cover a mechanism of action and is primarily on formulation of the product. All the four Indian companies with PCV ...
Pfizer buys AstraZeneca's Neksium antacid
Gelusil and Mucaine are two other drugs in the antacid space the company has
Pfizer fined $106 mn for 'unfair' prices of epilepsy drug
Flynn Pharma fined $6.55 million; CMA also ordered the companies to reduce their prices
Pfizer wins patent rights for autoimmune diseases' drug
The patent office dismissed the objections of two opponents and granted two process patents for Pfizer's etanercept
 "Pfizer wins patent rights for autoimmune diseases' drug")
Pfizer profit just misses estimates; company scraps cholesterol drug
The drugmaker earned 61 cents per share in the third quarter, excluding special items, missing the average analyst estimate by 1 cent
Pfizer concludes Rs 110 crore deal with Piramal Enterprises
Pfizer shares on Monday ended at Rs 1,930.40 apiece on the BSE, down 1.66% from previous close
Pfizer to purchase antibiotics business of AstraZeneca
Deal could be valued at more than $1.5 billion
Pfizer to buy US cancer drug company Medivation for $14 billion
Pfizer, Merck, Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to buy Medivation
Pfizer said close to $14-billion deal to acquire Medivation
The deal may be announced as early as Monday, said the people, who asked not to be identified because the matter is still private
Pfizer nears agreement to buy Medivation for $14 billion
Purchase would be Pfizer's biggest buy since it bought the medical device company Hospira last year for $17 billion
